Biotech
Major bio firm Alteogen seeks KOSPI listing
Ti AI ṣe iroyin Àwòrán tí AI ṣe
Alteogen, the top market cap company on South Korea's secondary KOSDAQ market, has decided to move to the main KOSPI bourse to secure stable funding and enhance its corporate value. Shareholders approved the proposal on Monday, with the firm aiming for a listing next year.
Chinese contract drug makers including WuXi AppTec, WuXi Biologics and WuXi XDC face a less certain long-term revenue outlook as US pharmaceutical companies reshore production amid US-China tensions. Cui Cui, head of healthcare research for Asia at Jefferies, said earnings visibility for 2026 and 2027 remains strong due to order backlogs, but longer-term order growth lacks clarity.
Ti AI ṣe iroyin
Gestala, a new entrant in China's expanding brain-computer interface sector, aims to connect with the brain using ultrasound technology without needing implants. This approach highlights the industry's shift toward less invasive methods. The company emerges amid rapid growth in Chinese biotech innovation.
Vaccine therapy for malignant glioma is advancing, with calls for expedited approvals to treat this aggressive brain cancer. The approach has potential to save lives and is part of efforts for rare disease treatments. Early results indicate effectiveness without traditional chemo or radiation.
Ti AI ṣe iroyin Ti ṣayẹwo fun ododo
A new treatment tested in brain organoids with glioblastoma outperformed chemotherapy and dramatically reduced tumors in mice. Human trials are upcoming. The approach also explores stem cell stimulation and aging cell rejuvenation for broader immunotherapy applications.